Epidemiological and Clinical Research Information Network
11
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.2%
2 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window
Role: collaborator
Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome
Role: collaborator
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Role: collaborator
Evaluation of an Endoscopic Sutured Gastroplasty in Patients With NonAlcoholic Steatohepatitis (NASH) and Fibrosis.
Role: collaborator
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Role: lead
XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer
Role: lead
XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer
Role: lead
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Role: collaborator
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
Role: collaborator
Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy
Role: collaborator
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Role: collaborator
All 11 trials loaded